Contents
1. The short answer
Chapter 9 of the EU Good Distribution Practice guidelines governs how medicinal products are transported. Its core demand is simple to state and hard to fake: the required storage conditions (temperature above all) must be maintained throughout transport and demonstrated with evidence. It is risk-based — the controls scale to how sensitive the product is — and it holds the wholesale distributor accountable for conditions from dispatch to delivery.
2. What Chapter 9 covers
Chapter 9 applies to the transport leg of distribution — the movement of medicinal products between authorised parties. It covers the transport process itself, the vehicles and equipment, and the containers and packaging used to protect the product. Crucially, it makes clear that responsibility for maintaining conditions does not disappear the moment product leaves the warehouse; the distributor must ensure conditions are held in transit, even when a third-party carrier does the driving.
3. The core requirements, in plain language
| Requirement | What it means in practice |
|---|---|
| Maintain conditions | Keep the product within its labelled temperature range for the whole journey. |
| Risk-based controls | Match the method (qualified packaging, monitored vehicle) to the product's sensitivity and the route's risk. |
| Demonstrate, don't assume | Use validated monitoring so you can show the conditions were held — not just assert it. |
| Qualify equipment & routes | Vehicles, containers and shipping lanes should be qualified for the conditions they must hold. |
| Protect against mix-ups & theft | Security and segregation controls travel with the product. |
| Handle deviations | A defined procedure for excursions — report, assess, decide, document. |
4. Excursions and deviations
Chapter 9 expects that when a temperature excursion occurs, it is detected, reported and assessed against the product's stability data — not waved through on an in-range average. The assessment and the release/reject disposition are a quality decision for the authorised person; the carrier's job is to maintain conditions and report deviations promptly. (We cover that split in detail in who decides a transit excursion.)
5. What you must be able to show an inspector
- Monitoring evidence — validated temperature data for the journey, with calibration status.
- Qualification records — for the packaging, vehicles and routes used.
- A deviation procedure — and evidence it was followed for any excursion, ending in a signed disposition (ALCOA+).
- Technical/quality agreements — with carriers, making responsibilities explicit.
- Traceability — the ability to reconstruct what moved, under what conditions, and who decided.
The last point is where most of the effort actually lands: turning raw logger files and shipment records into a defensible, reproducible account of each journey. That reconstruction is what Synlogica Terminus Transport (Terminus M1) and Quality (Terminus M4) are built to produce — freight-risk and excursion decisions with the input-data lineage recorded, so the number an inspector questions can be replayed exactly. Our companion piece on tender leakage covers the freight-risk side; the tender-leakage white paper has the full method.
6. FAQ
Is EU GDP Chapter 9 legally binding?
GDP guidelines are the standard EU inspectors hold wholesale distributors to, and a distribution authorisation depends on compliance. So while it is guidance in form, in practice Chapter 9 is enforced during GDP inspections.
Does Chapter 9 require temperature monitoring on every shipment?
It requires that transport conditions be maintained and demonstrated within the labelled range, using validated methods appropriate to risk. For temperature-sensitive products that means qualified packaging or monitored vehicles with evidence you can produce on request.
Who does Chapter 9 apply to — manufacturers or distributors?
Primarily wholesale distributors and anyone transporting medicinal products in the EU supply chain. Manufacturers follow GMP; once product is in distribution, GDP Chapter 9 governs how it moves.
7. References
- EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01), Chapter 9 — Transportation.
- EU GDP, Chapter 7 — Outsourced Activities; Chapter 3 — Premises and Equipment.
- USP General Chapter <1079> — Storage and Transportation of Finished Drug Products.